Skip to main content

Table 1 Patient recruited (PT) and expression datasets retrieved (PR) for this study.

From: Reconstruction and functional analysis of altered molecular pathways in human atherosclerotic arteries

Patient (PT)/Profile (PR) Sex Age (Years) Tissue sample Pathology/Lesion type Co-morbidities Pharmacological therapy Plasma lipid/Stenosis/ICR
PT1 M 50 LAD Ischemic/VII Hypothyroidism D;AAP;AC;HYR +/> 75%/5
PT2 F 68 LAD;AB Ischemic/VII None D;AC +/> 75%/4.6
PT3 M 66 LAD;AB Ischemic/VII Cholecystectomy AAP;HYR =/> 75%/5
PT4 M 64 LAD;AB Ischemic/VII None D;HYR +/> 75%/5.2
PT5 M 64 LAD;AB Ischemic/VI PAH D;ST;AAP;HYR +/> 75%/4.9
PT6 M 42 LAD;AB Ischemic/VII None D;HYR +/> 75%/5.3
PT7 M 53 LAD;AB Ischemic/VII Stone Kidney D;HYR;AAP +/> 75%/5.1
PT8 M 68 LAD Ischemic/VI None D;HYR;AAP +/> 75%/5.2
PT9 M 46 LAD;AB DCM/ctrl None D;AC +/-/4.6
PT10 M 48 LAD;AB DCM/ctrl Kidney pathology D;AC =/-/4.7
PT11 F 55 LAD;AB DCM/ctrl Thyroidectomy D;AC;CDR =/-/4.5
PT12 F 59 LAD;AB DCM/ctrl None BB;AC;AAP =/-/3.2
PT13 M 63 LAD;AB DCM/ctrl None ACEH;D;AC =/-/3.6
PT14 M 53 LAD;AB DCM/ctrl None ACEH;D;AAP +/-/3.8
PT15 M 62 LAD DCM/ctrl Gilbert's syndrome AAP =/-/3.5
PT16 M 61 LAD DCM/ctrl None ACEH;ST =/-/3.5
PT17 F 59 LAD DCM/ctrl None ACEH;AC;AAP =/-/4.3
PT18 F 41 LAD DCM/ctrl None D =/-/3.9
PT19 M 70 AB Ischemic/VII T2D D;HYR;SI +/> 75%/5
PT20 M 67 AB Ischemic/VII Mitral insufficiency None =/> 75%/4.3
PT21 F 82 AB Ischemic/VII HY None +/> 75%/4.6
PT22 M 63 AB Ischemic/VI None None =/> 75%/4.8
PT23 M 75 AB Ischemic/VI None ACEH;HYR +/> 75%/5.2
PT24 M 64 AB Ischemic/VII PD HYR;D;LD +/> 75%/5.1
PT25 M 75 AB Ischemic/VII T2D;HY SI;HYR +/> 75%/5.2
PT26 M 57 AB Ischemic/VII T2D;HY SI;HYR +/> 75%/5.5
PT27 M 66 AB Ischemic/VII HY HYR +/> 75%/5.2
PT28 M 69 AB Ischemic/VII HY HYR +/> 75%/5
PT29 M 51 AB Ischemic/VI None None =/> 75%/4.8
PT30 F 78 AB Ischemic/VII HY HYR +/> 75%/4.5
PT 31 M 75 AB Ischemic/VI None None =/> 75%/5.1
PR32* M 67 Carotid Ischemic Acute bronchitis NA NA/75%/NA
PR33* M 67 Carotid Ischemic Acute bronchitis NA NA/71%/NA
PR34* F 63 Carotid Ischemic CAD;T2D;HY NA NA/75%/NA
PR35* F 63 Carotid Ischemic CAD;T2D;HY NA NA/50%/NA
PR36* F 59 Carotid Ischemic HY;HYCH NA NA/75%/NA
PR37* F 59 Carotid Ischemic HY;HYCH NA NA/83%/NA
PR38* F 71 Carotid Ischemic CAD;T2D;HY;HYCH;AD NA NA/70%/NA
PR39* F 71 Carotid Ischemic CAD;T2D;HY;HYCH;AD NA NA/83%/NA
PR40† NA NA Coronary Normal NA NA NA
PR41† NA NA Coronary Normal NA NA NA
PR42† NA NA Coronary Normal NA NA NA
PR43‡ M NA Coronary Normal NA NA NA
PR44‡ M NA Coronary Normal NA NA NA
PR45‡ M NA Coronary Normal NA NA NA
  1. * PR of atherosclerotic carotids from E-MEXP-268, a study performed on carotid bilateral stenosis in which the two carotids (indicated by couple of consecutive numbers in the Table) of four independent patients have been analyzed. † PR of normal coronaries from GSE3526 (GSM80609, GSM80610, GSM80631). ‡ PR of normal coronaries from GSE7307 (GSM176115, GSM175820, GSM175821). ICR: index of cardiovascular risk; LAD: Left Anterior Descendent Coronary; AB: Arterial Blood; DCM/ctrl: Dilated Cardiomyopathy, used as pooled controls for microarray experiments; D: Diuretics; AAP: Anti-arrhythmics; AC: Anti-coagulants; HYR: Hypertension regulators; BB: Beta-blockers; ACEH: ACE inhibitors; ST: Statins; CDR: Cholesterol down-regulators; SI: Synthetic insulin; LD: Levodopa; PAH: Pulmonary hypertension; T2D: Type-2-diabetes; HY: Hypertension; HYCH: Hypercholesterolemia; PD: Parkinson's disease; AD: Artery disease; NA: not available.